Atacand Product Information
... angiotensin I to angiotensin II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II receptor antagonists are unlikely to be associated with cough. This has been confirmed in controlled clinical studies with ATACAND. Candesartan do ...
... angiotensin I to angiotensin II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II receptor antagonists are unlikely to be associated with cough. This has been confirmed in controlled clinical studies with ATACAND. Candesartan do ...
Product Monograph
... Pregnant Women: The safety of SALAGEN tablets has not been established in human pregnancy. There are no known human data for the effects of pilocarpine on fetal survival and development. Studies in animals have shown reproductive toxicity (see TOXICOLOGY). SALAGEN tablets should be used in pregnancy ...
... Pregnant Women: The safety of SALAGEN tablets has not been established in human pregnancy. There are no known human data for the effects of pilocarpine on fetal survival and development. Studies in animals have shown reproductive toxicity (see TOXICOLOGY). SALAGEN tablets should be used in pregnancy ...
Suggestion from clinicians
... spray (TANS); intranasal corticosteroid (INS) Proper management of AR, as with any chronic disease, is determined in part by patients’ acceptance and adherence to their treatment regimen, which is affected by factors such as efficacy, safety, dosing regimens, patient preference, and cost of treatmen ...
... spray (TANS); intranasal corticosteroid (INS) Proper management of AR, as with any chronic disease, is determined in part by patients’ acceptance and adherence to their treatment regimen, which is affected by factors such as efficacy, safety, dosing regimens, patient preference, and cost of treatmen ...
Controlling drug delivery
... systems to allow the effective, safe and reliable application of these bioactive compounds to the patient. It is important to realise that the active ingredient (regardless of whether this is a small-molecularweight ‘classical’ drug or a modern ‘biopharmaceutical’ drug like a therapeutic peptide, pr ...
... systems to allow the effective, safe and reliable application of these bioactive compounds to the patient. It is important to realise that the active ingredient (regardless of whether this is a small-molecularweight ‘classical’ drug or a modern ‘biopharmaceutical’ drug like a therapeutic peptide, pr ...
etoposide injection usp
... Etoposide should be considered a potential carcinogen in humans. The occurrence of acute leukemia with or without a preleukemic phase has been reported in rare instances in patients treated with etoposide alone or in association with other neoplastic agents. The risk of development of a preleukemic ...
... Etoposide should be considered a potential carcinogen in humans. The occurrence of acute leukemia with or without a preleukemic phase has been reported in rare instances in patients treated with etoposide alone or in association with other neoplastic agents. The risk of development of a preleukemic ...
Rohypnol and Gamma- hydroxybutyrate (GHB)
... Rohypnol is tasteless and odorless, and it dissolves easily in carbonated beverages. The sedative and toxic effects of Rohypnol are aggravated by concurrent use of alcohol. Even without alcohol, a dose of Rohypnol as small as 1 mg can impair a victim for 8 to 12 hours. Rohypnol is usually taken oral ...
... Rohypnol is tasteless and odorless, and it dissolves easily in carbonated beverages. The sedative and toxic effects of Rohypnol are aggravated by concurrent use of alcohol. Even without alcohol, a dose of Rohypnol as small as 1 mg can impair a victim for 8 to 12 hours. Rohypnol is usually taken oral ...
Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A
... to more than one cellular signal transduction pathway. Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same. In the current ...
... to more than one cellular signal transduction pathway. Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same. In the current ...
Full Product Information
... daily, it inhibits the late phase recruitment of inflammatory cells, notably eosinophils, in the skin and conjunctiva of atopic subjects submitted to antigen challenge, and the dose of 30 mg/day inhibits the influx of eosinophils in the bronchoalveolar lavage fluid during a late-phase bronchial cons ...
... daily, it inhibits the late phase recruitment of inflammatory cells, notably eosinophils, in the skin and conjunctiva of atopic subjects submitted to antigen challenge, and the dose of 30 mg/day inhibits the influx of eosinophils in the bronchoalveolar lavage fluid during a late-phase bronchial cons ...
Pharmacogenetic Testing Prior to Initiation of Warfarin
... due to a number of different genetic factors. Genetic variants may influence drug response by altering (1) drug metabolizing enzymes, (2) drug target(s) or receptor(s), and/or (3) drug transport protein(s) or a combination thereof.1 Pharmacogenetics is the investigation of the genetic basis of drug ...
... due to a number of different genetic factors. Genetic variants may influence drug response by altering (1) drug metabolizing enzymes, (2) drug target(s) or receptor(s), and/or (3) drug transport protein(s) or a combination thereof.1 Pharmacogenetics is the investigation of the genetic basis of drug ...
Safety Data Sheet Strength: 50/200mg. Pack Size: 30/90/100/500
... adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbance ...
... adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbance ...
What is cytarabine?
... Cytarabine is usually given once every 2 to 4 weeks. Follow your doctor's dosing instructions very carefully. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when cytarabine is injected. After receiving an injection in the space around your spinal cord, you will ...
... Cytarabine is usually given once every 2 to 4 weeks. Follow your doctor's dosing instructions very carefully. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when cytarabine is injected. After receiving an injection in the space around your spinal cord, you will ...
Nitro-Dur - Merck.com
... Nitrate ions liberated during metabolism of nitroglycerin can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b5 reductase activity, however, and even assuming that the nitrate moieties of nitroglycerin are quantitatively applied to oxidation of hemoglobin, about 1 ...
... Nitrate ions liberated during metabolism of nitroglycerin can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b5 reductase activity, however, and even assuming that the nitrate moieties of nitroglycerin are quantitatively applied to oxidation of hemoglobin, about 1 ...
formulation and in vitro evaluation of bilayered buccal patches of a
... granules and tablets have been developed1. PPIs are better antisecretory agents than H2 receptor antagonists (H2-RAs) 2, 3. ...
... granules and tablets have been developed1. PPIs are better antisecretory agents than H2 receptor antagonists (H2-RAs) 2, 3. ...
Toxicologic Pathology - Ocular Therapeutix, Inc.
... posterior segment during a prolonged period of time. Hydrophilic drugs, which penetrate through the sclera, are more effective when given by the subconjunctival route, because they do not have to penetrate the conjunctival epithelium. The angiostatic steroid anecortave (Retaane) is injected as a dep ...
... posterior segment during a prolonged period of time. Hydrophilic drugs, which penetrate through the sclera, are more effective when given by the subconjunctival route, because they do not have to penetrate the conjunctival epithelium. The angiostatic steroid anecortave (Retaane) is injected as a dep ...
ANALYTICAL METHODS FORTAXANES QUANTIFICATION IN DILUTED FORMULATIONS AND
... it is also more expensive. It can also be used in two distinct ways: off-line and on-line. Columns supplied as individual units and in a 96-well plate format for manual and automated use, respectively, are named off-line SPE, where samples are prepared separately from the LC-MS/MS equipment. In on-l ...
... it is also more expensive. It can also be used in two distinct ways: off-line and on-line. Columns supplied as individual units and in a 96-well plate format for manual and automated use, respectively, are named off-line SPE, where samples are prepared separately from the LC-MS/MS equipment. In on-l ...
nausea and vomiting - KSU Faculty Member websites
... are 2 to 3 times longer than that of ondansetron. These observations initially suggested that more frequent ondansetron administration would be required. However, it has now been shown that receptor blockade dose not correlate with elimination half-life and all 5HT3 antagonists can be effectively ad ...
... are 2 to 3 times longer than that of ondansetron. These observations initially suggested that more frequent ondansetron administration would be required. However, it has now been shown that receptor blockade dose not correlate with elimination half-life and all 5HT3 antagonists can be effectively ad ...
Package Insert - Phenobarbital Oral Solution, USP
... and maintaining sleep by the end of 2 weeks of continued drug administration even with the use of multiple doses. As with secobarbital sodium and pentobarbital sodium, other barbiturates (including amobarbital) might be expected to lose their effectiveness for inducing and maintaining sleep after 2 ...
... and maintaining sleep by the end of 2 weeks of continued drug administration even with the use of multiple doses. As with secobarbital sodium and pentobarbital sodium, other barbiturates (including amobarbital) might be expected to lose their effectiveness for inducing and maintaining sleep after 2 ...
EVALUATION OF ANALGESIC, ANTI-INFLAMMATORY AND ANTIPYRETIC POTENTIAL OF SWERTIA CORYMBOSA Research Article
... higher over the positive drug pentazocine. At the dose level 200 mg/kg and 240 min reaction time, the analgesic activity(8.90 ± 0.40 s) of the test extract was higher than that of the standard drug pentazocine (8.10 ± 0.90s). Thermic painful stimuli are known to be selective to centrally active drug ...
... higher over the positive drug pentazocine. At the dose level 200 mg/kg and 240 min reaction time, the analgesic activity(8.90 ± 0.40 s) of the test extract was higher than that of the standard drug pentazocine (8.10 ± 0.90s). Thermic painful stimuli are known to be selective to centrally active drug ...
Controlling drug delivery chapter 1 Over view
... The most important route of drug administration into the body is through mucosal membranes. Mucosal membranes are much less of a barrier to uptake than the skin and some mucosal membranes (such as the ones in the small intestine) are indeed specialised sites for absorption. There are many mucosal me ...
... The most important route of drug administration into the body is through mucosal membranes. Mucosal membranes are much less of a barrier to uptake than the skin and some mucosal membranes (such as the ones in the small intestine) are indeed specialised sites for absorption. There are many mucosal me ...
The Role of Molecular Imaging in Drug Delivery
... with 99mTc-labelled liposomes to estimate the effect of hyperthermia on intratumoural accumulation of doxorubicin in rat fibrosarcomas using scintigraphy. They found that co-administration of radiolabelled liposomes did not negatively influence the amount of drug delivered with doxorubicin and there ...
... with 99mTc-labelled liposomes to estimate the effect of hyperthermia on intratumoural accumulation of doxorubicin in rat fibrosarcomas using scintigraphy. They found that co-administration of radiolabelled liposomes did not negatively influence the amount of drug delivered with doxorubicin and there ...
Overview of Oral Modified-Release Opioid Products for
... to opioids due to tolerance and cross tolerance, pharmacokinetic and pharmacodynamic variability, use of coanalgesics and other CNS-active medications, and psychological variables. Third, clinicians should always use the same equianalgesic table to standardize their dose calculations between differe ...
... to opioids due to tolerance and cross tolerance, pharmacokinetic and pharmacodynamic variability, use of coanalgesics and other CNS-active medications, and psychological variables. Third, clinicians should always use the same equianalgesic table to standardize their dose calculations between differe ...
Molecular modification
... antidepressants. He described the first group of patients treated by alprazolam as so impressed by its action. The company soon knew outright that the drug was going to be a hit. A few of those patients even pooled their money and purchased stock in ...
... antidepressants. He described the first group of patients treated by alprazolam as so impressed by its action. The company soon knew outright that the drug was going to be a hit. A few of those patients even pooled their money and purchased stock in ...
CDISC Clinical Research Glossary
... FDA 21 CFR 310.305 defines an adverse drug experience to include any adverse event, “whether or not considered to be drug-related.” CDISC recognizes that current usage incorporates the concept of causality. [WHO Technical Report 498(1972); ICH E2A] adverse event (AE). Any untoward medical occurrence ...
... FDA 21 CFR 310.305 defines an adverse drug experience to include any adverse event, “whether or not considered to be drug-related.” CDISC recognizes that current usage incorporates the concept of causality. [WHO Technical Report 498(1972); ICH E2A] adverse event (AE). Any untoward medical occurrence ...